TTNP (Titan Pharmaceuticals) Cyclically Adjusted FCF per Share: $-446.67 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TTNP Titan Pharmaceuticals Inc TTNP
9 GF Score
Price $4.61
View Full Analysis

What is Titan Pharmaceuticals Cyclically Adjusted FCF per Share?

Titan Pharmaceuticals TTNP 9 Cyclically Adjusted FCF per Share is $-446.67 as of Jun. 2025. GuruFocus rates TTNP with a GF Score™ of 9/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Titan Pharmaceuticals's adjusted free cash flow per share for the three months ended in Jun. 2025 was $-0.638. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-446.67 for the trailing ten years ended in Jun. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-17), Titan Pharmaceuticals's current stock price is $4.61. Titan Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2025 was $-446.67. Titan Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Titan Pharmaceuticals  (NAS:TTNP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Titan Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Titan Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Titan Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Titan Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Titan Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,476.12 -985.47 -979.28 -680.67 -524.58

Titan Pharmaceuticals Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -601.17 -566.24 -524.58 -485.75 -446.67

TTNP vs TCRT, SXTP, KTTA: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Titan Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Titan Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Titan Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


TTNP
9GF Score
Titan Pharmaceuticals Inc TTNP
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Titan Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Titan Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2025 (Change)*Current CPI (Jun. 2025)
=-0.638/322.5610*322.5610
=-0.638

Current CPI (Jun. 2025) = 322.5610.

Titan Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201509 -301.500 237.945 -408.717
201512 -305.500 236.525 -416.626
201603 -349.167 238.132 -472.963
201606 2,252.667 241.018 3,014.806
201609 -469.333 241.428 -627.055
201612 -413.833 241.432 -552.894
201703 -522.667 243.801 -691.515
201706 -420.000 244.955 -553.063
201709 -612.333 246.819 -800.241
201712 -587.000 246.524 -768.052
201803 -176.167 249.554 -227.705
201806 -308.500 251.989 -394.898
201809 -381.000 252.439 -486.833
201812 -166.045 251.233 -213.187
201903 -197.818 254.202 -251.014
201906 -182.087 256.143 -229.302
201909 -130.231 256.759 -163.607
201912 -39.323 256.974 -49.359
202003 -37.986 258.115 -47.470
202006 -25.570 257.797 -31.994
202009 -23.871 260.280 -29.583
202012 -12.801 260.474 -15.852
202103 -5.657 264.877 -6.889
202106 -3.917 271.696 -4.650
202109 -4.588 274.310 -5.395
202112 -2.184 278.802 -2.527
202203 -5.530 287.504 -6.204
202206 -2.580 296.311 -2.809
202209 -2.562 296.808 -2.784
202212 -2.154 296.797 -2.341
202303 -2.529 301.836 -2.703
202306 -1.481 305.109 -1.566
202309 -2.443 307.789 -2.560
202312 -2.975 306.746 -3.128
202403 -0.719 312.332 -0.743
202406 -2.263 314.175 -2.323
202409 -0.758 315.301 -0.775
202412 -0.554 315.605 -0.566
202503 -0.949 319.799 -0.957
202506 -0.638 322.561 -0.638

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-446.67 mean?
Titan Pharmaceuticals (TTNP) has a Cyclically Adjusted FCF per Share of $-446.67 as of Jun. 2025. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Titan Pharmaceuticals and its competitors.
Is Titan Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Titan Pharmaceuticals' current Cyclically Adjusted FCF per Share is $-446.67. Overall, Titan Pharmaceuticals has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Titan Pharmaceuticals' Cyclically Adjusted FCF per Share compare to TCRT and SXTP?
Titan Pharmaceuticals' Cyclically Adjusted FCF per Share of $-446.67 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Titan Pharmaceuticals and its competitors. Titan Pharmaceuticals's current Cyclically Adjusted FCF per Share is $-446.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Pharmaceuticals stock overvalued right now?
Titan Pharmaceuticals (TTNP) has a current Cyclically Adjusted FCF per Share of $-446.67. The current Cyclically Adjusted FCF per Share is $-446.67. Titan Pharmaceuticals' overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Titan Pharmaceuticals (TTNP), the current Cyclically Adjusted FCF per Share is $-446.67 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Titan Pharmaceuticals Business Description

Address 400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
9GF Score

Get the complete analysis for TTNP

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.61
Price